272 related articles for article (PubMed ID: 34108939)
21. Dysregulation of Parkin-mediated mitophagy in thyroid Hürthle cell tumors.
Lee J; Ham S; Lee MH; Kim SJ; Park JH; Lee SE; Chang JY; Joung KH; Kim TY; Kim JM; Sul HJ; Kweon GR; Jo YS; Kim KS; Shong YK; Gasparre G; Chung JK; Porcelli AM; Shong M
Carcinogenesis; 2015 Nov; 36(11):1407-18. PubMed ID: 26354775
[TBL] [Abstract][Full Text] [Related]
22. The value of epigenetic biomarkers in breast cancer.
Parrella P
Biomark Med; 2018 Sep; 12(9):937-940. PubMed ID: 30041537
[No Abstract] [Full Text] [Related]
23. Epigenetics application in the diagnosis and treatment of bladder cancer.
Harb-de la Rosa A; Acker M; Kumar RA; Manoharan M
Can J Urol; 2015 Oct; 22(5):7947-51. PubMed ID: 26432963
[TBL] [Abstract][Full Text] [Related]
24. Cancer type-specific epigenetic changes: gastric cancer.
Calcagno DQ; de Arruda Cardoso Smith M; Burbano RR
Methods Mol Biol; 2015; 1238():79-101. PubMed ID: 25421656
[TBL] [Abstract][Full Text] [Related]
25. Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.
Musholt PB; Musholt TJ; Morgenstern SC; Worm K; Sheu SY; Schmid KW
World J Surg; 2008 May; 32(5):722-8. PubMed ID: 18235983
[TBL] [Abstract][Full Text] [Related]
26. [Developing technologies for epigenomic analysis and clinical application of molecular diagnosis].
Yamamoto E; Suzuki H; Maruyama R; Shinomura Y
Rinsho Byori; 2012 Jul; 60(7):637-43. PubMed ID: 22973723
[TBL] [Abstract][Full Text] [Related]
27. DNA methylation aberrancies delineate clinically distinct subsets of colorectal cancer and provide novel targets for epigenetic therapies.
Weisenberger DJ; Liang G; Lenz HJ
Oncogene; 2018 Feb; 37(5):566-577. PubMed ID: 28991233
[TBL] [Abstract][Full Text] [Related]
28. [Lung cancer and epigenetic modifications].
Darılmaz Yüce G; Ortaç Ersoy E
Tuberk Toraks; 2016 Jun; 64(2):163-70. PubMed ID: 27481083
[TBL] [Abstract][Full Text] [Related]
29. Defective ciliogenesis in thyroid hürthle cell tumors is associated with increased autophagy.
Lee J; Yi S; Kang YE; Chang JY; Kim JT; Sul HJ; Kim JO; Kim JM; Kim J; Porcelli AM; Kim KS; Shong M
Oncotarget; 2016 Nov; 7(48):79117-79130. PubMed ID: 27816963
[TBL] [Abstract][Full Text] [Related]
30. Early Epigenetic Markers for Precision Medicine.
Dumitrescu RG
Methods Mol Biol; 2018; 1856():3-17. PubMed ID: 30178243
[TBL] [Abstract][Full Text] [Related]
31. Does the fine-needle aspiration diagnosis of "Hürthle-cell neoplasm/follicular neoplasm with oncocytic features" denote increased risk of malignancy?
Giorgadze T; Rossi ED; Fadda G; Gupta PK; Livolsi VA; Baloch Z
Diagn Cytopathol; 2004 Nov; 31(5):307-12. PubMed ID: 15468114
[TBL] [Abstract][Full Text] [Related]
32. Reduced HBME-1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma-related neoplastic lesions with Hürthle cell and/or apocrine-like changes.
Mai KT; Bokhary R; Yazdi HM; Thomas J; Commons AS
Histopathology; 2002 Feb; 40(2):133-42. PubMed ID: 11952857
[TBL] [Abstract][Full Text] [Related]
33. Hürthle cell lesions of the thyroid: Progress made and challenges remaining.
Wong KS; Angell TE; Barletta JA; Krane JF
Cancer Cytopathol; 2021 May; 129(5):347-362. PubMed ID: 33108684
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic Alterations in the Gastrointestinal Tract: Current and Emerging Use for Biomarkers of Cancer.
Grady WM; Yu M; Markowitz SD
Gastroenterology; 2021 Feb; 160(3):690-709. PubMed ID: 33279516
[TBL] [Abstract][Full Text] [Related]
35. EIF1AX Mutation in a Patient with Hürthle Cell Carcinoma.
Topf MC; Wang ZX; Furlong K; Miller JL; Tuluc M; Pribitkin EA
Endocr Pathol; 2018 Mar; 29(1):27-29. PubMed ID: 28965201
[TBL] [Abstract][Full Text] [Related]
36. CHL1 expression differentiates Hürthle cell carcinoma from benign Hürthle cell nodules.
Li W; Xia S; Aronova A; Min IM; Verma A; Scognamiglio T; Gray KD; Ullmann TM; Liang H; Moore MD; Elemento O; Zarnegar R; Fahey TJ
J Surg Oncol; 2018 Nov; 118(6):1042-1049. PubMed ID: 30311656
[TBL] [Abstract][Full Text] [Related]
37. Epigenome Remodeling in Cholangiocarcinoma.
O'Rourke CJ; Lafuente-Barquero J; Andersen JB
Trends Cancer; 2019 Jun; 5(6):335-350. PubMed ID: 31208696
[TBL] [Abstract][Full Text] [Related]
38. Analysis of Hurthle cell neoplasms of the thyroid by interphase fluorescence in situ hybridization.
Erickson LA; Jalal SM; Goellner JR; Law ME; Harwood A; Jin L; Roche PC; Lloyd RV
Am J Surg Pathol; 2001 Jul; 25(7):911-7. PubMed ID: 11420462
[TBL] [Abstract][Full Text] [Related]
39. Remodeling epigenetic modifications at tumor suppressor gene promoters with bovine oocyte extract.
Wang Z; Yue Y; Han P; Sa R; Ren X; Wang J; Bai H; Yu H
Cytotherapy; 2013 Sep; 15(9):1164-73. PubMed ID: 23800731
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic and epitranscriptomic changes in colorectal cancer: Diagnostic, prognostic, and treatment implications.
Porcellini E; Laprovitera N; Riefolo M; Ravaioli M; Garajova I; Ferracin M
Cancer Lett; 2018 Apr; 419():84-95. PubMed ID: 29360561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
